Fucosylated C4b‑binding protein α‑chain, a novel serum biomarker that predicts lymph node metastasis in pancreatic ductal adenocarcinoma

Sogawa,Kazuyuki; Yamanaka,Sakino; Takano,Shigetsugu; Sasaki,Kosuke; Miyahara,Yoji; Furukawa,Katsunori; Takayashiki,Tsukasa; Kuboki,Satoshi; Takizawa,Hirotaka; Nomura,Fumio; Ohtsuka,Masayuki

doi:10.3892/ol.2020.12388

Fucosylated C4b‑binding protein α‑chain, a novel serum biomarker that predicts lymph node metastasis in pancreatic ductal adenocarcinoma

Authors:
- Kazuyuki Sogawa
- Sakino Yamanaka
- Shigetsugu Takano
- Kosuke Sasaki
- Yoji Miyahara
- Katsunori Furukawa
- Tsukasa Takayashiki
- Satoshi Kuboki
- Hirotaka Takizawa
- Fumio Nomura
- Masayuki Ohtsuka
View Affiliations

Affiliations: Department of Biochemistry, School of Life and Environmental Science, Azabu University, Sagamihara, Kanagawa 252‑5201, Japan, Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba 260‑8670, Japan, Kashiwado Clinic in Port‑Square, Kashiwado Memorial Foundation, Chiba 260‑0025, Japan, Divisions of Clinical Mass Spectrometry and Clinical Genetics, Chiba University Hospital, Chiba 260‑8670, Japan
Published online on: December 17, 2020 https://doi.org/10.3892/ol.2020.12388
Article Number: 127
Copyright: © Sogawa et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

C4b‑binding protein α‑chain (C4BPA) was previously identified as a novel serum biomarker for pancreatic ductal adenocarcinoma (PDAC). To apply this biomarker for clinical diagnosis, a lectin ELISA was established to measure serum fucosylated (Fuc)‑C4BPA levels in 45 patients with PDAC, 20 patients with chronic pancreatitis (CP) and 50 healthy volunteers (HVs) in one training and three validation sets. The lecithin ELISA developed in the current study exhibited satisfactory within‑run (2.6‑6.7%) and between‑day (1.8‑3.6%) coefficient of variations. Serum Fuc‑C4BPA levels in patients with PDAC (0.54±0.27 AU/ml) was significantly higher than that in HVs (0.21±0.06 AU/ml; P<0.0001) and patients with CP (0.25±0.03 AU/ml; P<0.0001). Additionally, serum Fuc‑C4BPA levels in preoperative patients were significantly decreased compared with postoperative patient sera (P<0.0003). The receiver operating characteristic (ROC) curve analyses revealed that the area under the curve (AUC) of Fuc‑C4BPA (0.985) was higher than that of carbohydrate antigen (CA)19‑9 (0.843), carcinoembryonic antigen (0.548) and total C4BPA (0.875) (P<0.001). To analyze the clinical significance of Fuc‑C4BPA, the ability of Fuc‑C4BPA to predict lymph node metastasis was compared with that of CA19‑9. The AUC of serum Fuc‑C4BPA levels (0.703) was significantly higher than that of serum CA19‑9 levels (0.500) in patients with PDAC (P<0.001). The current study established a novel lectin ELISA for measuring serum Fuc‑C4BPA levels. Thus, Fuc‑C4BPA has potential clinical applications owing to its high diagnostic value in PDAC.

View Figures

View References

1	Takano S, Yoshitomi H, Togawa A, Sogawa K, Shida T, Kimura F, Shimizu H, Tomonaga T, Nomura F and Miyazaki M: Apolipoprotein C-1 maintains cell survival by preventing from apoptosis in pancreatic cancer cells. Oncogene. 27:2810–2822. 2008. View Article : Google Scholar
2	Moulder R, Bhosale SD, Goodlett DR and Lahesmaa R: Analysis of the plasma proteome using iTRAQ and TMT-based Isobaric labeling. Mass Spectrom Rev. 37:583–606. 2018. View Article : Google Scholar
3	Bhawal R, Oberg AL, Zhang S and Kohli M: Challenges and opportunities in clinical applications of blood-based proteomics in cancer. Cancers (Basel). 12:24282020. View Article : Google Scholar
4	Sogawa K, Takano S, Iida F, Satoh M, Tsuchida S, Kawashima Y, Yoshitomi H, Sanda A, Kodera Y, Takizawa H, et al: Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags. Br J Cancer. 115:949–956. 2016. View Article : Google Scholar
5	Mikami M, Tanabe K, Matsuo K, Miyazaki Y, Miyazawa M, Hayashi M, Asai S, Ikeda M, Shida M, Hirasawa T, et al: Fully-sialylated alpha-chain of complement 4-binding protein: Diagnostic utility for ovarian clear cell carcinoma. Gynecol Oncol. 139:520–528. 2015. View Article : Google Scholar
6	Liu YS, Luo XY, Li QR, Li H, Li C, Ni H, Li RX, Wang R, Hu HC, Pan YJ, et al: Shotgun and targeted proteomics reveal that pre-surgery serum levels of LRG1, SAA, and C4BP may refine prognosis of resected squamous cell lung cancer. J Mol Cell Biol. 4:344–347. 2012. View Article : Google Scholar
7	Jia L, Zhang J, Ma T, Guo Y, Yu Y and Cui J: The function of fucosylation in progression of lung cancer. Front Oncol. 8:5652018. View Article : Google Scholar
8	Li D and Satomura S: Biomarkers for hepatocellular carcinoma (HCC): An update. Adv Exp Med Biol. 867:179–193. 2015. View Article : Google Scholar
9	Jelski W and Mroczko B: Biochemical diagnostics of pancreatic cancer-Present and future. Clin Chim Acta. 498:47–51. 2019. View Article : Google Scholar
10	Tanabe K, Matsuo K, Miyazawa M, Hayashi M, Ikeda M, Shida M, Hirasawa T, Sho R and Mikami M: UPLC-MS/MS based diagnostics for epithelial ovarian cancer using fully sialylated C4-binding protein. Biomed Chromatogr. 32:e41802018. View Article : Google Scholar
11	Umemura H, Nezu M, Kodera Y, Satoh M, Kimura A, Tomonaga T and Nomura F: Effects of the time intervals between venipuncture and serum preparation for serum peptidome analysis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chim Acta. 406:179–180. 2009. View Article : Google Scholar
12	Narimatsu H, Iwasaki H, Nakayama F, Ikehara Y, Kudo T, Nishihara S, Sugano K, Okura H, Fujita S and Hirohashi S: Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res. 58:512–518. 1998.
13	Kawa S, Oguchi H, Kobayashi T, Tokoo M, Furuta S, Kanai M and Homma T: Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype. Br J Cancer. 64:899–902. 1991. View Article : Google Scholar
14	Stanczyk FZ and Clarke NJ: Advantages and challenges of mass spectrometry assays for steroid hormones. J Steroid Biochem Mol Biol. 121:491–495. 2010. View Article : Google Scholar
15	Farrell CJ, Martin S, McWhinney B, Straub I, Williams P and Herrmann M: State-of-the-art vitamin D assays: A comparison of automated immunoassays with liquid chromatography-tandem mass spectrometry methods. Clin Chem. 58:531–542. 2012. View Article : Google Scholar
16	Soldin SJ, Soukhova N, Janicic N, Jonklaas J and Soldin OP: The measurement of free thyroxine by isotope dilution tandem mass spectrometry. Clin Chim Acta. 358:113–118. 2005. View Article : Google Scholar
17	Reis ES, Mastellos DC, Ricklin D, Mantovani A and Lambris JD: Complement in cancer: Untangling an intricate relationship. Nat Rev Immunol. 18:15–18. 2018. View Article : Google Scholar
18	Muinelo-Romay L, Vazquez-Martin C, Villar-Portela S, Cuevas E, Gil-Martín E and Fernández-Briera A: Expression and enzyme activity of alpha (1,6) fucosyltransferase in human colorectal cancer. Int J Cancer. 123:641–646. 2008. View Article : Google Scholar
19	Moriwaki K, Noda K, Furukawa Y, Ohshima K, Uchiyama A, Nakagawa T, Taniguchi N, Daigo Y, Nakamura Y, Hayashi N and Miyoshi E: Deficiency of GMDS leads to escape from NK cell-mediated tumor surveillance through modulation of TRAIL signaling. Gastroenterology. 137:188–198. 2009. View Article : Google Scholar
20	Lambert A, Schwarz L, Borbath I, Henry A, Van Laethem JL, Malka D, Ducreux M and Conroy T: An update on treatment options for pancreatic adenocarcinoma. Ther Adv Med Oncol. 11:17588359198755682019. View Article : Google Scholar
21	Tran Cao HS, Zhang Q, Sada YH, Silberfein EJ, Hsu C, Van Buren G II, Chai C, Katz MHG, Fisher WE and Massarweh NN: Value of lymph node positivity in treatment planning for early stage pancreatic cancer. Surgery. 162:557–567. 2017. View Article : Google Scholar
22	Roche CJ, Hughes ML, Garvey CJ, Campbell F, White DA, Jones L and Neoptolemos JP: CT and pathologic assessment of prospective nodal staging in patients with ductal adenocarcinoma of the head of the pancreas. AJR Am J Roentgenol. 180:475–480. 2003. View Article : Google Scholar
23	Tseng DS, van Santvoort HC, Fegrachi S, Besselink MG, Zuithoff NP, Borel Rinkes IH, van Leeuwen MS and Molenaar IQ: Diagnostic accuracy of CT in assessing extra-regional lymphadenopathy in pancreatic and peri-ampullary cancer: A systematic review and meta-analysis. Surg Oncol. 23:229–235. 2014. View Article : Google Scholar
24	Nishiwada S, Sho M, Banwait JK, Yamamura K, Akahori T, Nakamura K, Baba H and Goel A: A microRNA signature identifies pancreatic ductal adenocarcinoma patients at risk for lymph node metastases. Gastroenterology. 159:562–574. 2020. View Article : Google Scholar